Cardinal Health 414 patents expiration
1. Lymphoseek Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(1 year, 7 months from now) | |
| US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Jan, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 19, 2024 |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
Market Authorisation Date: 13 March, 2013
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
LYMPHOSEEK KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic